Abstract:Senescence refers to a cellular state marked by irreversible cell cycle arrest and the secretion of pro-inflammatory and tissue-remodeling factors. The senescence associated secretory phenotype (SASP) impacts the tissue microenvironment and provides cues for the immune system to eliminate senescent cells (SCs). Cellular senescence has a dual nature; it can be beneficial during embryonic development, tissue repair, and tumor suppression, but it can also be detrimental in the context of chronic stress, persistent tissue injury, together with an impairment in SC clearance. Recently, the accumulation of SCs has been implicated in the pathogenesis of pulmonary arterial hypertension (PAH), a progressive condition affecting the pre-capillary pulmonary arterial bed. PAH is characterized by endothelial cell (EC) injury, inflammation, and proliferative arterial remodeling, which leads to right heart failure and premature mortality. While vasodilator therapies can improve symptoms, there are currently no approved treatments capable of reversing the obliterative arterial remodeling. Ongoing endothelial injury and dysfunction is central to the development of PAH, perpetuated by hemodynamic perturbation leading to pathological intimal shear stress. The precise role of senescent ECs in PAH remains unclear. Cellular senescence may facilitate endothelial repair, particularly in the early stages of disease. However, in more advanced disease the accumulation of senescent ECs may promote vascular inflammation and occlusive arterial remodeling. In this review, we will examine the evidence that supports a role of endothelial cell senescence to the pathogenesis of PAH. Furthermore, we will compare and discuss the apparent contradictory outcomes with the use of interventions targeting cellular senescence in the context of experimental models of pulmonary hypertension. Finally, we will attempt to propose a framework for the understanding of the complex interplay between EC injury, senescence, inflammation and arterial remodeling, which can guide further research in this area and the development of effective therapeutic strategies.

The role of senescence in the pathogenesis of atrial fibrillation: A target process for health improvement and drug development

The role of cellular senescence in profibrillatory atrial remodeling associated with cardiac pathology

Identification of senescence-related genes for potential therapeutic biomarkers of atrial fibrillation by bioinformatics, human histological validation, and molecular docking

Premature Senescence of Cardiac Fibroblasts and Atrial Fibrosis in Patients with Atrial Fibrillation

Senescent CD8+ T cells: a novel risk factor in atrial fibrillation

Pathophysiology, molecular mechanisms, and genetics of atrial fibrillation

Targeting Cellular Senescence to Combat Cancer and Ageing

Understanding the Intricacies of Cellular Senescence in Atherosclerosis: Mechanisms and Therapeutic Implications

Pathophysiological mechanisms of atrial fibrillation: a translational appraisal.

Aging and atrial fibrillation: A vicious circle

Cellular Senescence as a Targetable Risk Factor for Cardiovascular Diseases: Therapeutic Implications: JACC Family Series

Targeting Autophagy in Atrial Fibrillation

Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective

Cardiac cell senescence: molecular mechanisms, key proteins and therapeutic targets

A Review of the Molecular Mechanisms Underlying Cardiac Fibrosis and Atrial Fibrillation

Cellular Senescence: Mechanisms and Therapeutic Potential

Senescence and tissue fibrosis: opportunities for therapeutic targeting

Cellular senescence in the pathogenesis of pulmonary arterial hypertension: the good, the bad and the uncertain

Targeting senescent cells in atherosclerosis: Pathways to novel therapies

Prevention of Atrial Fibrillation: Putting Proteostasis Derailment Back on Track

Atrial Fibrillation in Aging Population.